{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:44:01Z","timestamp":1791654241289,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.drudis.2022.04.013","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T19:01:25Z","timestamp":1650481285000},"page":"2322-2332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Novel and investigational therapies for wet and dry age-related macular degeneration"],"prefix":"10.1016","volume":"27","author":[{"given":"Aira","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srushti","family":"Jayesh Sodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayabhaskarreddy","family":"Junnuthula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kolimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathish","family":"Dyawanapelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.04.013_b0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.drudis.2022.04.013_b0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2020","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.drudis.2022.04.013_b0015","unstructured":"AMDF. Dry vs wet age-related macular degeneration. www.macular.org\/dry-vs-wet-macular-degeneration [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0020","doi-asserted-by":"crossref","first-page":"AMD12","DOI":"10.1167\/iovs.17-23203","article-title":"Local progression kinetics of geographic atrophy in age-related macular degeneration are associated with atrophy border morphology","volume":"59","author":"Lindner","year":"2018","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jama.2016.0783","article-title":"Screening for impaired visual acuity in older adults: a systematic review to update the 2009 U.S. Preventive Services Task Force","volume":"315","author":"Chou","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2022.04.013_b0035","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2147\/OPTH.S207978","article-title":"Issues with intravitreal administration of anti-VEGF drugs","volume":"14","author":"Schargus","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39301","article-title":"Sustained elevation of intraocular pressure associated with intravitreal administration of anti-vascular endothelial growth factor: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.04.013_b0045","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","article-title":"Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials","volume":"121","author":"Bakri","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/jop.2014.0062","article-title":"High intraocular pressure following anti-vascular endothelial growth factor therapy: Proposed pathophysiology due to altered nitric oxide metabolism","volume":"31","author":"Ricca","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.drudis.2022.04.013_b0055","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.3390\/ijms221910594","article-title":"Ocular therapeutics and molecular delivery strategies for neovascular age-related macular degeneration (nAMD)","volume":"22","author":"Sarkar","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0060","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41433-021-01830-5","article-title":"The port delivery system with ranibizumab\u2014journey of mitigating vitreous hemorrhage","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2022.04.013_b0065","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jconrel.2020.10.054","article-title":"Nanodiagnostics and nanotherapeutics for age-related macular degeneration","volume":"329","author":"Sarkar","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2022.04.013_b0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized Phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/bjophthalmol-2020-316195","article-title":"Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions","volume":"105","author":"de Guimaraes","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0080","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/07853890600946724","article-title":"Age-related macular degeneration-emerging pathogenetic and therapeutic concepts","volume":"38","author":"Gehrs","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.drudis.2022.04.013_b0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/09273940590909185","article-title":"Immunological factors in the pathogenesis and treatment of age-related macular degeneration","volume":"13","author":"Kijlstra","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.drudis.2022.04.013_b0090","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/14656566.2019.1636031","article-title":"Innovative therapies for neovascular age-related macular degeneration","volume":"20","author":"Al-khersan","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.drudis.2022.04.013_b0095","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the Phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0105","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Reports"},{"key":"10.1016\/j.drudis.2022.04.013_b0110","unstructured":"Novartis. Brolucizumab. www.brolucizumab.info\/ [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy","volume":"55","author":"Pl\u00fcckthun","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2022.04.013_b0120","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ophtha.2020.03.035","article-title":"Efficacy and safety of abicipar in neovascular age-related macular degeneration","volume":"127","author":"Kunimoto","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0125","first-page":"2311","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2022.04.013_b0130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized Phase 3 PHOENIX study","volume":"197","author":"Liu","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0135","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","article-title":"Safety and efficacy of conbercept in neovascular age-related macular degeneration","volume":"121","author":"Li","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0140","first-page":"4286","article-title":"Updated results of Phase 1b study of KSI-301, an anti-VEGF antibody biopolymer conjugate with extended durability, in wAMD, DME, and RVO","volume":"61","author":"Patel","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nbt0297-159","article-title":"Design and production of novel tetravalent bispecific antibodies","volume":"15","author":"Coloma","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2022.04.013_b0150","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.oret.2017.03.003","article-title":"Phase I trial of anti-vascular endothelial growth factor\/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration","volume":"1","author":"Chakravarthy","year":"2017","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.drudis.2022.04.013_b0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.exer.2016.02.004","article-title":"IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys","volume":"145","author":"Ren","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2022.04.013_b0160","first-page":"1201","article-title":"Therapeutic effect of IBI302, a bispecific Fc-fusion protein, on age-related macular degeneration","volume":"55","author":"Wang","year":"2014","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0165","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2022.04.013_b0170","unstructured":"Roche. Study to evaluate faricimab (RO6867461; RG7716) for extended durability in the treatment of neovascular age related macular degeneration (STAIRWAY). https:\/\/forpatients.roche.com\/en\/trials\/eye-disorder\/amd\/study-to-evaluate-ro6867461--rg7716--for-extended-durability-in-.html [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0175","unstructured":"Roche. FDA accepts application for Roche\u2019s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). www.roche.com\/investors\/updates\/inv-update-2021-07-29b.htm [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0180","unstructured":"Biogen. FDA approves Samsung Bioepis and Biogen\u2019s BYOOVIZTM (SB11), LUCENTIS\u00ae biosimilar (ranibizumab-nuna). https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11 [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0185","unstructured":"Outlook Therapeutics. Outlook Therapeutics reports positive efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 \/ LYTENAVATM (bevacizumab-vikg) for the treatment of wet AMD. https:\/\/ir.outlooktherapeutics.com\/news-releases\/news-release-details\/outlook-therapeutics-reports-positive-efficacy-and-safety-data [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration","volume":"129","author":"Holz","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0195","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/OPTH.S180393","article-title":"Biosimilars in ophthalmology: Is there a big change on the horizon?","volume":"12","author":"Sharma","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.exer.2016.02.010","article-title":"Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models","volume":"145","author":"Giddabasappa","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2022.04.013_b0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/adt.2019.920","article-title":"Axitinib-loaded poly(lactic-co-glycolic acid) nanoparticles for age-related macular degeneration: formulation development and in vitro characterization","volume":"17","author":"Narvekar","year":"2019","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.drudis.2022.04.013_b0210","first-page":"2966","article-title":"Inhibition of choroidal neovascularization (CNV) by X-82 in a subretinal matrigel CNV model","volume":"50","author":"Huang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0215","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamaophthalmol.2017.1571","article-title":"Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration","volume":"135","author":"Jackson","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0220","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bjophthalmol-2020-316511","article-title":"APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration","volume":"105","author":"Cohen","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0225","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","article-title":"Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration","volume":"22","author":"Hussain","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.drudis.2022.04.013_b0230","first-page":"4805","article-title":"Final results from a Phase 2 study of squalamine lactate ophthalmic solution 0.2% (OHR-102) in the treatment of neovascular age-related macular degeneration (AMD)","volume":"56","author":"Slakter","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0235","unstructured":"PanOptica. A new wave of innovation in neovascular eye disease. www.panopticapharma.com\/ [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/bjophthalmol-2020-316195","article-title":"Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions","volume":"105","author":"de Guimaraes","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0245","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","article-title":"Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives","volume":"24","author":"Bordet","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2022.04.013_b0250","doi-asserted-by":"crossref","first-page":"e19078","DOI":"10.1371\/journal.pone.0019078","article-title":"A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration","volume":"6","author":"Cashman","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.04.013_b0255","unstructured":"Adverum Biotechnologies. Adverum Biotechnologies presents long-term data through March 10, 2021 from the OPTIC Trial of ADVM-022 intravitreal gene therapy in treatment-experienced wet AMD patients at ARVO 2021. https:\/\/investors.adverum.com\/news\/news-details\/2021\/Adverum-Biotechnologies-Presents-Long-term-Data-through-March-10-2021-from-the-OPTIC-Trial-of-ADVM-022-Intravitreal-Gene-Therapy-in-Treatment-experienced-Wet-AMD-Patients-at-ARVO-2021-2021-5-1-2021-5-1\/default.aspx [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0260","unstructured":"REGENXBIO. RGX-314. www.regenxbio.com\/rgx-314\/ [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0265","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal Phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0270","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0041-1345(03)00356-7","article-title":"The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation","volume":"35","author":"Camardo","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.drudis.2022.04.013_b0275","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized Phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0280","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","article-title":"Characterizing new-onset exudation in the randomized Phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy","volume":"128","author":"Wykoff","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0285","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1164\/rccm.202007-2778LE","article-title":"Complement inhibition with the C5 blocker LFG316 in severe COVID-19","volume":"202","author":"Zelek","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2022.04.013_b0290","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1381612822666161221154424","article-title":"Hot topics in dry AMD","volume":"23","author":"Narayanan","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.drudis.2022.04.013_b0295","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.04.013_b0300","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/13543784.2020.1763953","article-title":"Risuteganib\u2014a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema","volume":"29","author":"Shaw","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2022.04.013_b0305","first-page":"2126","article-title":"Mitochondrial dysfunction in experimental mouse models of SubRPE deposit formation and reversal by the Mito-Reparative drug MTP-131","volume":"57","author":"Cousins","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0310","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.10.8.4","article-title":"The present and future of mitochondrial-based therapeutics for eye disease","volume":"10","author":"Ji","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.drudis.2022.04.013_b0315","first-page":"1","article-title":"Recent advances in the management of dry age-related macular degeneration: a review","volume":"6","author":"Querques","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.drudis.2022.04.013_b0320","first-page":"913","article-title":"A pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration","volume":"51","author":"Ralston","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0325","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/13543784.2013.794782","article-title":"Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial","volume":"22","author":"Augustin","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2022.04.013_b0330","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.ajpath.2014.07.017","article-title":"The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning","volume":"184","author":"Mullins","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2022.04.013_b0335","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b\u20139","volume":"144","author":"Rollins","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2022.04.013_b0340","doi-asserted-by":"crossref","first-page":"e19078","DOI":"10.1371\/journal.pone.0019078","article-title":"A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration","volume":"6","author":"Cashman","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.04.013_b0345","first-page":"2295","article-title":"GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)","volume":"61","author":"Ellis","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22270","article-title":"Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review","volume":"22","author":"Waugh","year":"2018","journal-title":"Health Technol Assess (Rockv)"},{"key":"10.1016\/j.drudis.2022.04.013_b0355","first-page":"514","article-title":"New treatment modalities for neovascular age-related macular degeneration","volume":"6","author":"Schlottmann","year":"2017","journal-title":"Asia-Pac J Ophthalmol Phila PA"},{"key":"10.1016\/j.drudis.2022.04.013_b0360","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/OPTH.S194234","article-title":"Therapeutic potential of the ranibizumab port delivery system in the treatment of AMD: evidence to date","volume":"14","author":"Chen","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.04.013_b0365","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.04.013_b0370","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.04.013_b0375","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized Phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0380","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.04.013_b0385","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/IAE.0000000000002614","article-title":"Evaluation of surgical factors affecting vitreous hemorrhage following port delivery system with ranibizumab implant insertion in a minipig model","volume":"40","author":"Bantseev","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2022.04.013_b0390","unstructured":"Roche. FDA approves Roche\u2019s Susvimo, a first-of-its-kind therapeutic approach for neovascular or \u2018wet\u2019 age-related macular degeneration (nAMD). www.roche.com\/media\/releases\/med-cor-2021-10-22b.htm [Accessed April 12, 2022]."},{"key":"10.1016\/j.drudis.2022.04.013_b0395","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.addr.2012.02.005","article-title":"Reservoir-based drug delivery systems utilizing microtechnology","volume":"64","author":"Stevenson","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2022.04.013_b0400","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41433-020-0809-0","article-title":"Advances in ocular drug delivery systems","volume":"34","author":"Kang-Mieler","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2022.04.013_b0405","first-page":"5037","article-title":"GB-102 for Wet AMD: a novel injectable formulation that safely delivers active levels of sunitinib to the retina and RPE\/Choroid for over four months","volume":"57","author":"Yang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0410","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/tvst.9.3.30","article-title":"Safety and biocompatibility of aflibercept-loaded microsphere thermo-responsive hydrogel drug delivery system in a nonhuman primate model","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.drudis.2022.04.013_b0415","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41433-020-0770-y","article-title":"Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases","volume":"34","author":"Seah","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2022.04.013_b0420","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/IAE.0000000000002789","article-title":"Phase 2 study of the safety and efficacy of brimonidine drug delivery system (brimo dds) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration","volume":"41","author":"Kuppermann","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2022.04.013_b0425","first-page":"971","article-title":"Phase 2b study of brimonidine DDS: potential novel treatment for geographic atrophy","volume":"60","author":"Freeman","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.04.013_b0430","unstructured":"Retinal Pharma Market: Market Size, Growth Forecasts, and Market Share | Market Scope. https:\/\/www.market-scope.com\/pages\/reports\/273\/2021-retinal-pharmaceuticals-market-report#reports. Accessed January 21, 2022."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:08Z","timestamp":1761224408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462200160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S135964462200160X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.04.013","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel and investigational therapies for wet and dry age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}